OBJECTIVES: To evaluate the long-term outcomes of patients with high Gleason sum 8-10 at radical prostatectomy (RP) and to identify the predictors of prostate cancer-specific survival (CSS) in this cohort. METHODS: The institutional RP database was queried. A total of 9381 patients with complete follow-up underwent RP from 1982 to 2008. Of these 9381 patients, 1061 had pathologic Gleason sum 8-10 cancer. The patient and prostate cancer characteristics were evaluated. Survival analyses were performed using the Kaplan-Meier method. Univariate and multivariate proportional hazard regression models were created to evaluate the pertinent predictors of CSS (death from, or attributed to, prostate cancer). RESULTS: The median preoperative prostate-specific antigen level was 7.6 ng/mL; 435 men had clinical Stage T1 tumor, 568 had Stage T2, and 36 had Stage T3. The biopsy Gleason sum was <7, 7, and >7 in 244 (22.3%), 406 (37.2%), and 425 (38.9%) patients, respectively. The median follow-up was 5 years (range 1-23). The actuarial 15-year recurrence-free survival, CSS, and overall survival rate was 20.7%, 57.4%, and 45.4%, respectively. On multivariate analysis, the predictors of poor CSS were pathologic Gleason sum 9-10 and seminal vesicle and lymph node involvement. Patients with pathologic Gleason sum 8 and organ-confined disease had a CSS rate of 89.9% at 15 years. CONCLUSIONS: The results of our study have shown that 80% of the men with Gleason sum 8-10 who undergo RP will have experienced biochemical recurrence by 15 years. However, the CSS rate approached 90% for men with pathologic organ-confined disease. Higher pathologic Gleason sum 9-10 and seminal vesicle and lymph node involvement were independent predictors of worse CSS.
OBJECTIVES: To evaluate the long-term outcomes of patients with high Gleason sum 8-10 at radical prostatectomy (RP) and to identify the predictors of prostate cancer-specific survival (CSS) in this cohort. METHODS: The institutional RP database was queried. A total of 9381 patients with complete follow-up underwent RP from 1982 to 2008. Of these 9381 patients, 1061 had pathologic Gleason sum 8-10 cancer. The patient and prostate cancer characteristics were evaluated. Survival analyses were performed using the Kaplan-Meier method. Univariate and multivariate proportional hazard regression models were created to evaluate the pertinent predictors of CSS (death from, or attributed to, prostate cancer). RESULTS: The median preoperative prostate-specific antigen level was 7.6 ng/mL; 435 men had clinical Stage T1 tumor, 568 had Stage T2, and 36 had Stage T3. The biopsy Gleason sum was <7, 7, and >7 in 244 (22.3%), 406 (37.2%), and 425 (38.9%) patients, respectively. The median follow-up was 5 years (range 1-23). The actuarial 15-year recurrence-free survival, CSS, and overall survival rate was 20.7%, 57.4%, and 45.4%, respectively. On multivariate analysis, the predictors of poor CSS were pathologic Gleason sum 9-10 and seminal vesicle and lymph node involvement. Patients with pathologic Gleason sum 8 and organ-confined disease had a CSS rate of 89.9% at 15 years. CONCLUSIONS: The results of our study have shown that 80% of the men with Gleason sum 8-10 who undergo RP will have experienced biochemical recurrence by 15 years. However, the CSS rate approached 90% for men with pathologic organ-confined disease. Higher pathologic Gleason sum 9-10 and seminal vesicle and lymph node involvement were independent predictors of worse CSS.
Authors: M V Tefilli; E L Gheiler; R Tiguert; M Banerjee; W Sakr; D Grignon; D P Wood; J E Pontes Journal: Prostate Date: 1999-04-01 Impact factor: 4.104
Authors: G S Gerber; R A Thisted; P T Scardino; H G Frohmuller; F H Schroeder; D F Paulson; A W Middleton; D B Rukstalis; J A Smith; P F Schellhammer; M Ohori; G W Chodak Journal: JAMA Date: 1996-08-28 Impact factor: 56.272
Authors: S E Schild; W W Wong; G L Grado; M Y Halyard; D E Novicki; S K Swanson; T R Larson; R G Ferrigni Journal: Int J Radiat Oncol Biol Phys Date: 1996-02-01 Impact factor: 7.038
Authors: M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart Journal: N Engl J Med Date: 1997-07-31 Impact factor: 91.245
Authors: D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: Patrick J Bastian; Mark L Gonzalgo; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Joseph C Presti; Leslie A Mangold; Elizabeth Humphreys; Jonathan I Epstein; Alan W Partin; Stephen J Freedland Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Phillip M Pierorazio; Ashley E Ross; Misop Han; Jonathan I Epstein; Alan W Partin; Edward M Schaeffer Journal: BJU Int Date: 2011-08-22 Impact factor: 5.588
Authors: F O'Kelly; S Elamin; A Cahill; P Aherne; J White; J Buckley; K N O'Regan; A Brady; D G Power; M F O'Brien; P Sweeney; N Mayer; P J Kelly Journal: World J Urol Date: 2013-10-16 Impact factor: 4.226
Authors: Phillip M Pierorazio; Ashley E Ross; Brian M Lin; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Christian P Pavlovich; Edward M Schaeffer Journal: BJU Int Date: 2012-02-28 Impact factor: 5.588
Authors: Jonas Busch; Ahmed Magheli; Natalia Leva; Stefan Hinz; Michelle Ferrari; Frank Friedersdorff; Tom Florian Fuller; Kurt Miller; Mark L Gonzalgo Journal: World J Urol Date: 2014-03-09 Impact factor: 4.226
Authors: Phillip M Pierorazio; Jeffrey K Mullins; John B Eifler; Kipp Voth; Elias S Hyams; Misop Han; Christian P Pavlovich; Trinity J Bivalacqua; Alan W Partin; Mohamad E Allaf; Edward M Schaeffer Journal: BJU Int Date: 2013-01-28 Impact factor: 5.588
Authors: Paula J Hurley; Luigi Marchionni; Brian W Simons; Ashley E Ross; Sarah B Peskoe; Rebecca M Miller; Nicholas Erho; Ismael A Vergara; Mercedeh Ghadessi; Zhenhua Huang; Bora Gurel; Ben Ho Park; Elai Davicioni; Robert B Jenkins; Elizabeth A Platz; David M Berman; Edward M Schaeffer Journal: Proc Natl Acad Sci U S A Date: 2012-08-27 Impact factor: 11.205
Authors: Giovanna Danza; Claudia Di Serio; Maria Raffaella Ambrosio; Niccolò Sturli; Giuseppe Lonetto; Fabiana Rosati; Bruno Jim Rocca; Giuseppina Ventimiglia; Maria Teresa del Vecchio; Igor Prudovsky; Niccolò Marchionni; Francesca Tarantini Journal: Int J Cancer Date: 2013-06-26 Impact factor: 7.396